Overview of the drug development for Dengue
Dengue is a mosquito-borne tropical disease caused by the dengue virus which is a single positive-stranded RNA virus. Aedes mosquito is the major cause for the transmission of Dengue. Dengue is one of the most common diseases which is prevalent in tropical and subtropical regions. Aedes mosquitos can breed in optimal rainfall environment and can carry the disease. Dengue is prevalent in 100 countries in Asia, the Pacific, the Americas, Africa, and the Caribbean. It has been observed that most of the dengue cases were reported in 48 continental states. Based on the CDC reports, the WHO estimated that 50-100 million infections occur yearly, which consists of 50,0000 DHF cases and 22,000 deaths, mostly among children.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for Dengue. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Want a bigger picture? Try a FREE sample of this report now!
Drug development for Dengue market research report: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of Dengue. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the gene therapy molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
- Abivax
- BioNet-Asia
- Codagenix
Therapeutic assessment of drug development for Dengue by route of administration
- Oral
- Subcutaneous
- Intramuscular
The oral route of administration involves the application of drugs directly through the mouth cavity.
Therapeutic assessment of the drug development for Dengue by therapy
- Monotherapy
- Monotherapy/combination therapy
- Combination therapy
According to this pipeline analysis report, most of the molecules that are currently in the drug development for Dengue are being developed as monotherapy drugs. In this technique, a single drug is used to treat a particular disorder.
Key questions answered in the report include
- What are the drug molecules in the various development stages for Dengue?
- What are the companies that are currently involved in the drug development for Dengue?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.